Abstract Ovarian epithelial carcinomas are heterogeneous malignancies exhibiting great diversity in histological phenotypes as well as genetic and epigenetic aberrations.
Introduction
Ovarian cancer is consistently one of the leading causes of cancer-related mortality among women. Approximately 90% of ovarian cancers are ovarian epithelial carcinomas (OECs), arising principally from the fimbriae of the fallopian tube, but sometimes originating from dysplastic inclusion cysts derived from modified ovarian surface epithelium (OSE) [1] . Regional dissemination from direct peritoneal contact is a frequent early event, occurring well before distant metastasis via hematogenous or lymphatic routes.
Ovarian cancers are classified by the type of Müllerian histology exhibited by malignant cells, as well as by invasive potential. The predominant histological subtype is serous adenocarcinoma, followed by endometrioid and the rarer mucinous, undifferentiated and clear cell carcinomas. Type I low grade, or low malignancy potential tumors, are characterized by a gradual accruement of morphological and genetic changes over time. These carcinomas progress slowly from borderline tumors and often display high mutation rates of KRAS, BRAF, and ERBB2 [2, 3] . The remaining malignancies are type II high grade carcinomas. Tumors with this classification exhibit a highly invasive phenotype very rapidly with more widespread chromosomal instability (CIN) and pronounced epigenetic alterations of gene expression. Ras mutations are uncommon in high grade OEC. While TP53 mutations are relatively rare in low grade carcinomas, they present in up to 97% of high grade serous tumors [4] .
Because ovarian carcinomas are highly heterogeneous, the structural changes and molecular interactions that take place within the tumor microenvironment of the extracellular matrix (ECM) and on the cell surface may provide key insights into ovarian cancer progression, including tumor genesis, development and metastasis. In addition, delineating the changes in expression patterns of extracellular ligands that alter signaling cascades during transformation toward a mitogenic phenotype should have direct implications on the discovery of novel biomarkers for diagnosis and therapeutic targets for intervention.
Despite the variegated nature of OEC, direct peritoneal dissemination is a hallmark of early disease. Malignancies showing only regional spread from the primary tumor site are far more curable than those carcinomas that have metastasized to distant tissues. For this reason, knowledge of the early events predisposing to tumorigenesis and peritoneal invasion is critical in elucidating common mechanisms in the pathogenesis of different forms of OEC. As patterns in alterations to the microenvironment that fosters and facilitates tumor genesis and growth are better recognized, identification of unifying factors across broad spectra of otherwise different diseases manifesting as ovarian carcinomas will present opportunities for clinicians to diagnose OEC more rapidly and possibly offer more successful treatment options as well. The following review briefly highlights areas of research that have contributed to our understanding of the elusive tumor microenvironment in OEC, with emphasis on the cross-talk and signaling between components that prepare the tissue for malignancy.
Cell-matrix Transitions Mediated by Cadherins
Specialized junctions, such as adherens and tight junctions, are responsible for holding epithelial cells together. Important mediators of cell-cell interactions in adherens junctions are members of transmembrane proteins belonging to the cadherin superfamily (Table 1) . Normal OSE derived from the coelomic layer expresses N-cadherin [5] . E-cadherin is not found in physiologic OSE but is highly expressed in surface clefts and inclusion cysts [6] . Cells transplanted from contiguous tissue, such as those from the fallopian tube epithelium, are likely sources of increased E-cadherin. Epithelial-like characteristics of newly migrated cells appear to provoke a mesenchymal-to-epithelial (MTE) transition and subsequent switch to Müllerian duct histology within the ovary [7] . This sudden up-regulation of E-cadherin leads to a gain of function effect responsible for inducing an anomalous hyperdifferentiated state very different from dedifferentiation typically observed in cancers. Cells within the ovary then resemble those confined to nearby tissue [8] . For example, cells destined for serous carcinoma take on a Fallopian tube-like histology, clear cell carcinoma cells present with a vaginal phenotype, mucinous carcinoma cells display an endocervical histology, and endometrioid carcinoma cells show an endometrial histology. The observed phenotypes appear to reflect the source of invasive cells from adjacent tissue, making ovarian cancer and amalgam of different primary cancers.
Following the MTE transition, ovarian epithelial cells are not yet in a state promoting excessive proliferation, survival and invasiveness that would favor a shift to a tumorigenic phenotype. High concentrations of E-cadherin are associated with β-catenin transcriptional inactivity, as they bind to one another on the cell surface to prevent nuclear translocation and subsequent transcription of the Sphase regulator cyclin D1 and oncogenes such as c-Myc [9] . In addition, E-cadherin interacts with epithelial growth factor receptor (EGFR) to weaken its ligand affinity [10] . A dampened EGFR ligand response in E-cadherin-positive cells, as well as pre-dysplastic N-cadherin expressing cells, is believed to be involved in growth suppression via contact inhibition due to increased p27 expression [11, 12] .
Peritoneal dissemination is not capable of occurring until an epithelial-to-mesenchymal (EMT) reversal takes place following initial MTE transition. Epithelial-like adhesive qualities exhibited by newly implanted cells may be overridden by inhibitory signaling localized within the microenvironment of the transcoelomic mesothelium.
While epithelial cells exhibit apical/basolateral polarity on a basement membrane with strong adhesive characteristics, mesenchymal cells display a front/back polarity within an interstitial matrix, endowing them with the ability to invade the basal lamina, the major barrier to cell migration. The potential for EMT reversal is high in OSE cells, as these mesothelial-like cells exhibit reversible mesenchymal characteristics due to their regenerative capacity in post-ovulatory repair [13] .
Because of the inhibitory effects on growth induced by E-cadherin when expressed in the ovary, its [12, [123] [124] [125] [126] H-cadherin (+) Down-regulated Cell recognition, contact inhibition, p21 expression [127, 128] P-cadherin (−) Expressed after regional metastasis GnRH-dependent p120 activation, cell invasion [5, 26, 123, 129] repression is vital in the commencement toward EMT. A major transcriptional repressor of E-cadherin is Snail1 [14] . Several growth factors and related proteins up-regulate Snail1, including EGF, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), p70 S6 kinase, nuclear factor-kappa beta (NF-κβ) and integrin-linked kinase (ILK), which are often highly expressed in OEC [15] [16] [17] (Table 2 ). An inverse relationship between E-cadherin loss and α 5 β 1 integrin has additionally been observed, consistent with remodeling associated with EMT transition to an invasive phenotype [46] . The membrane trafficking protein responsible for displaying α 5 β 1 integrin at the cell surface is Rab25, and tumor development has been shown to be facilitated by enhanced Rab25 activity [47] .
Key downstream signaling pathways involved in cell growth, survival and migration become activated through the formation of a submembrane signalosome complex consisting of the cytoplasmic domains of integrins as well as associated proteins. These include the MEK/ERK and PI3K/Akt pathways [48] [49] [50] . Activation of the PI3K pathway has been linked to resistance to apoptosis in lung and ovarian cancer [50, 51] . Proteins acting as mediators for signal transduction upon binding to β integrin subunits in signalosome formation include ILK and focal adhesion kinase (FAK). ILK functions in both structural arrangement of molecules and cell signaling. This focal adhesion plaque component is involved in integrin and growth factor binding to cytoskeletal actin and causes nuclear translocation of β-catenin via inhibition of GSK-3β [52, 53] . β-catenin is a binding partner of E-cadherin that induces transcriptional activity of Snail-1 and cyclin D1 when present in the nucleus [54] . The non-receptor kinase, FAK, is activated by autophosphorylation following galectin, talin or paxillin interaction with β 1 integrin, and becomes phosphorylated at additional sites in response to growth factors to regulate different signaling pathways [55, 56] . Activation of FAK plays a part in the development of anchorage-independent tumor aggregates in ascites to promote metastatic potential by overriding anoikis, which causes cell death upon disassociation from the ECM under normal circumstances [57, 58] .
Integrin expression has been correlated with angiogenesis. Activation of both VEGF and FGF is associated with increased α v expression [59] . Endothelial cell proliferation is associated with α 5 β 1 binding to fibronectin in the ECM [60] . In addition, pericyte adhesion and differentiation is regulated in part by β 1 subunit-mediated signaling [61] . Taken together, these data show a critical role for integrins in not only tumor initiation and invasion, but in neovascularization necessary for tumor growth as well.
Metastasis and angiogenesis related with altered β 1 integrin signaling is due in part to alterations in carbohydrate binding characteristics. The sialyltransferase ST6Gal-I is frequently overexpressed in ovarian cancer, and this enzyme has been shown to increase branched α2,6-sialylation of the β 1 subunit, altering its adhesion characteristics to favor an invasive phenotype [62] . In addition, hypoglycosylated variants of mucin-1 (MUC1) are common in OEC [63] . Mucins are large proteins heavily Oglycosylated on proline-threonine-serine tandem repeat sites that form a protective barrier on the surface of epithelial cells. Alternate splice variants lacking these domains instead feature short oligosaccharides, including Thomsen-Friedenreich (TF) antigen [64] . Without the protective barrier of O-glycosylated MUC1 on the cell surface, the TF antigen in its asialylated form enhances galectin-3 binding to β 1 integrin, facilitating both cell motility and angiogenesis [65, 66] .
MMPs and Growth Factors in Matrix Remodeling
The transformation of a microenvironment conducive to creation of large scale ostensible alterations in cell polarity and cytoskeletal binding characteristics involves the actions of a number of proteases for degradation and growth factors for remodeling. Signaling mediated by EGF and HB-EGF with the EGFR receptor helps to promote a shift toward a pro-survival and pro-proliferative state, while MMP activation is critical in breaking down the substratum to favor migration and invasion. Although overexpression of several MMPs is subsumed in the malignant phenotype, MMP-2, MMP-9 and membrane type-1 (MT1)-MMP have particularly important known functions in tumorigenesis and metastasis [67] .
MMPs constituting the gelatinase subfamily (MMP-2, MMP-9) are necessary for non-specific degradation of a number of ECM components during the large scale remodeling needed for EMT transition. MMP expression is hormonally regulated in healthy ovaries by LH in response to the need for tissue remodeling during ovulation to support follicular growth. These proteases additionally maintain the corpus luteum and dissolve the follicular wall and corpus luteum in post-ovulatory repair [68] . Gelatinase concentrations are especially high, as they localize around developing follicles to support their growth. Larger follicles KLK15 unfavorable Regulation of activation of proKLKs [136] over 25 mm diameter are associated with increased amounts of MMP-9 [69]. The serine protease responsible for activation of most MMPs, including the transmembrane type MT1-MMP and MMP-9, is urokinase plasminogen activator (uPA) bound to its uPAR receptor [70, 71] . Activation of the uPA/uPAR complex is mediated by several microenvironmental constituents, including lysophosphatidic acid (LPA) and VEGF [72, 73] . MT1-MMP is a key regulatory MMP in modulating the pericellular microenvironment, and its expression stimulates cooperative communication with integrins during ECM remodeling as well as activation of MMP-2, which is otherwise not directly expressed by uPA [68, 74] . Tight junction proteins in the claudin family are thought to play a role in MMP expression as well. Claudin-3 and claudin-4 are frequently expressed in OEC, as they aid in altering membrane permeability to facilitate invasion. Both of these proteins have been implicated in gelatinase activation [75, 76] .
Growth Factors in EMT and Angiogenesis
When the inhibitory effects on proliferation and invasion mediated by E-cadherin are abrogated through its inactivation, EGFR is then freed by the changing microenvironment to enhance its ligand binding affinity to EGF and HB-EGF. MMP-9 activity is strongly correlated with increased EGFR activity [43, 77] . EGFR activation in the OSE facilitates a number of EMT inducing events, including suppression of the pro-apoptotic cyclin inhibitor protein p27, increased β 1 and particularly α 5 β 1 signaling, activation of VEGF, ERK, and ILK, decreased caveolin-1 expression, and increased gelatinase expression [43, 46, 78] .
A major EGFR ligand observed in OEC cells is HB-EGF [43] . This growth factor is highly expressed proportionately as disease pathology progresses, yielding high concentrations in advanced stages and ascites in particular [79] . HB-EGF contains a heparan sulfate binding motif that enables its binding to heparan sulfate proteoglycans (HSPG) in the coelomic epithelium. An analysis of HSPG expression in normal OSE compared to that derived from tumors evinced normal patterns for all cell surface PGs except syndecan-1 (SDC1), which was highly expressed in tumor cells but absent from normal epithelium [80] . In addition, only SDC1 and glypican-1 were associated with poor prognoses in univariate analysis. It can thus be inferred that induction of SDC1 is a critical factor in EGFR activation upon heparan sulfate binding to HB-EGF to enable cell surface accumulation of this ligand. Hypersulfation of HSPGs secondary to inactivation of the arylsulfatase HSulf-1 is a common event in OEC, and may contribute to neovascularization by increasing binding capacity of endothelial cells to the heparin-binding domains of VEGF A and FGF [81] .
The cross-talk between MMPs and growth factors is apparent during angiogenesis. Both MMP-2 and MMP-9 induce expression of VEGF, and VEGF, in turn, can induce expression of MMP-9 [82, 83] . VEGF plays an important role in stromal invasion and neovascularization upon binding to endothelial cells, and is one of the most predominant angiogenic agents in tumor formation. Nerve growth factor (NGF), through its tyrosine kinase A (TrkA) receptor, is another potent angiogenic factor. Downstream signaling via the PI3K/Akt pathway induces MMP-2 [84] . This effect is likely due to increased expression of its activator, MT1-MMP [85] . In breast cancer cells, TrkA receptor-mediated signaling by NGF through both the PI3K/Akt and MAPK/ERK2 pathways were shown to activate MMP-2 and VEGF, as well as endothelial nitric oxide synthase (eNOS) [86] . This produces a highly invasive phenotype with high vascular permeability to strongly favor angiogenesis. Hormonal effects of NGF/TrkA interactions include an antiluteinization effect via progesterone inhibition coupled with follicle stimulating hormone receptor (FSHR) and estrogen sensitization [87] . Overexpression of gonadotropins, such as FSH and LH, is associated with OEC progression, and progesterone is believed to have an inhibitory effect, as both progestin-only contraceptives and pregnancy, which is characterized by elevated progesterone levels, are associated with risk reduction. Because of the ubiquitous nature of NGF in establishing the tumor microenvironment and facilitating angiogenesis, phosphorylated TrkA has recently been proposed as a potential biomarker for EOC [88] .
Negative Regulation of Growth Factors and MMPs
With the large degree of matrix-associated remodeling necessary for tumorigenesis, it is reasonable to asseverate that there will be a paucity of negative regulators of growth factors and MMPs as cells become more invasive and resistant to death with disease progression. Indeed, this is what is observed. Growth factor regulation is often attributed to solubility. As a general rule, soluble growth factor receptors have inhibitory functions and intact receptors promote survival, growth and proliferation. One potential biomarker for OEC is the lack of soluble (s)EGFR. This receptor is a secretory splice variant that inhibits tyrosine kinase activity when bound to its ligand. The amount of sEGFR progressively decreases with age and with advancing stages of OEC [89, 90] . Its reduction is additionally correlated with increased gonadotropin con-centrations [89] . Other potential risk and disease markers are TIMP family inhibitors of MMPs. TIMP1 is specific for MMP-9 inactivation, while TIMP2 inhibits MMP-2 and TIMP3 suppresses both MT1-MMP and MMP-9. Decreased levels of these three TIMPs have been associated with OEC through LPA-mediated interactions [91] .
Not much information is available regarding negative regulation of angiogenic growth factors. Two candidate markers that may impact future ovarian cancer research are G-protein receptor kinase 5 (GRK5) and neurotrophin receptor-interacting MAGE homolog (NRAGE). In a study by Zhou et al., expression of GRK5 in human coronary artery endothelial cells reduced VEGF signaling to abrogate cell proliferation and migration [92] . Activation of TrkA-mediated signaling upon interaction with NGF is inhibited by NRAGE [93] . This has been demonstrated to cause a significant reduction in MMP-2 expression and diminished motility and invasion in melanoma and pancreatic cancer cells both in vitro and in vivo [94] . NRAGE is a binding partner of BRCA2 that negatively regulates cell proliferation in a p53-independent manner, and is down-regulated in 37.5% of breast cancer cell lines studied [95] . Despite the strong association between ovarian cancer and BRCA2 gene inactivation through either mutation or loss of heterozygosity, the possibility of altered NRAGE expression in OEC has yet to be examined.
GPCRs in the Regulation of Tumor Development
A major convergence point of several mechanisms that lead to peritoneal dissemination and spreading of EMTconverted cells derived from the ovary is the activation of GPCRs. These receptors regulate many aspects of tumor growth and development, such as cell growth, cell survival, motility, cytoskeletal remodeling, angiogenesis, cell cycle progression and chemotaxis [96] . Two principal ligands involved in GPCR-mediated processes are LPA and ET-1, and their tumorigenic activities are mainly exerted through LPA 2 , LPA 3 , and ET A R.
LPA
LPA is a phospholipid that exerts its effects upon binding to one of five GPCRs, designated LPA [1] [2] [3] [4] [5] . Of these receptors, LPA [1] [2] [3] are extracellular receptors and LPA 1 has an inhibitory role in inflammation and growth regulation. LPA is produced by enzymatic activity of either ATX or PLA 2 . ATX expression is growth factor dependent, and it has been shown to be up-regulated by bFGF, EGF and VEGF [97, 98] . The peritoneal mesothelium constitutively produces PLA 2 , so translocated ovarian cells are constantly exposed to its presence [99] . Of particular concern in OEC is the secreted form of PLA 2 (sPLA 2 ). This isoform displays little activity in intact membranes but has high affinity for microvesicles similar to those found in ascites [100] . Expression of sPLA 2 has been shown to stimulate cell invasion [101] .
Receptor binding to LPA 2 , and to some extent LPA 3 , activates a number of signaling pathways important in tumor development and metastasis. GPCR-mediated LPAinduced events include FAK phosphorylation, NF-κβ upregulation and activation of the PI3K and MAPK/ERK pathways [42] . Phosphorylated FAK may be required to override anoikis in ascitic fluid, and NF-κβ affects transcription of several factors involved in cell growth, endothelial permeabilization and cell migration, such as Snail1, IL-6 and IL-8 [57, 102, 103] . ERK activation associated with LPA-mediated GPCR binding induces expression of sphingosine kinase 1 (SphK1), which phosphorylates sphingosine to generate S1P [104] . When phosphorylated by SphK1, but not the inhibitory SphK2, S1P stimulates endothelial cell proliferation and migration to trigger neovascularization [105] . High concentrations of sphingosine-1-phosphate (S1P) are observed in ovarian cancer cells [106] .
Hypoxia caused by ascites is a contributing factor toward mitogenic activity. A major angiogenic effect of LPA is its ability to activate VEGF under the hypoxic conditions within peritoneal fluid. Transcription of VEGF is up-regulated through LPA-mediated activation of HIF-1α [107] . A cooperative effect is possibly exerted by α v integrin-bound OPN. Induction of HIF-1α has been observed in ovarian cancer cells under normoxic conditions from overexpression of OPN via PI3K/Akt activation [108] . Not surprisingly, VEGF has been demonstrated to be up-regulated in endothelial cells, leading to neovascularization, and these effects have been inhibited by administration of anti-OPN and anti-α v β 3 antibodies [109] . Cross-talk is possible as LPA-mediated signaling was shown to induce OPN expression via Akt activation in a hepatic cancer cell line [110] .
ET-1
ET-1 is an endothelial vasoconstricting peptide that normally functions in smooth muscle cell contractions. Tumorigenic effects mediated through binding to ET A R. Like LPA, this ligand is found in high concentrations in ascitic fluid and exhibits redundancy in stimulating many of the same pathways [111] . A major effect of ET A R activation is induction of the ILK pathway, leading to Snail1 and β-catenin nuclear localization and activation [112] . Phosphorylation of FAK and activation of the MAPK and PI3K/Akt transduction cascades are also mediated by ET-1/ET A R binding [113, 114] . Increased expression of β1 integrins and disrupted gap junction communication has been linked to ET-1 as well [115, 116] . The latter phenomenon has been attributed to ET-1-mediated phosphorylation of connexin 43 [116] .
EGFR Transactivation by GPCRs
Both LPA and ET-1 can promote EGFR transactivation through their GPCRs. Although several molecules have been associated with EGFR transactivation in different cancer types, OEC cells have shown a close association between GPCR signaling mediated by LPA and ET-1 and activation of the HB-EGF ligand [117, 118] . Transactivation of EGFR is often the result of GPCRmediated activation of members of the ADAM family of metalloproteases [119] . The enzyme displaying the greatest correlation to HB-EGF activity is ADAM-17, but ADAM-9 and -12 have also been implicated [120] . The major mechanism for EGFR transactivation by GPCR signaling appears to be proteolytic cleavage of HB-EGF from its transmembrane precursor to its active soluble form by the sheddase activity of ADAM-17. Once in soluble form, HB-EGF can then phosphorylate its receptor to initiate multiple mitogenic signals from at least five distinct pathways (PI3K/Akt, Ras/p44/42/ MAPK, MEKK/p38 MAPK, PLC/PKC, Rho-GEF/ RhoA), which increase the invasive and proliferative nature of cells [117, 121] . It is therefore apparent that the alterations in the microenvironment caused by GPCRmediated signaling contribute to EMT transition in a number of different ways, making these receptors important upstream regulators of tumor formation and sustenance (Fig. 1) .
Conclusion
The preceding exposition elucidated several commonly occurring mechanisms factoring in the early stages of tumor formation and initial dissemination into the peritoneum, which is central to the transformation from local dysplasia to fully invasive malignancy. Discernment of the pathophysiology of ovarian cancer reveals several possible molecular markers while providing clues on where to hone in for finding possible drug targets, as large scale changes in tumor microenvironment as well as gene expression leave researchers with an arduous task on deciphering the most important developments that may be of therapeutic relevance. Because of the high propensity for outside-in signaling coordinated by the tissue matrix toward the activity of constituent cells, a thorough investigation of events unfolding in the tumor microenvironment will indubitably reveal signal modulators that regulate several downstream effectors and thus should serve as better therapeutic targets than any one of the redundant markers individually. Much further research is required before a more comprehensive depiction of the microenvironment that provides the necessary conditions required for development and metastasis of tumors can be achieved. Advancements in proteomics, transcriptomics and glycomics should reveal patterns that will help to uncover additional components to better understand the transformation of the tumor microenvironment in ovarian carcinoma. 
